A Microdose Evaluation Study of ABY-029 in Primary Sarcoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 30, 2017

Primary Completion Date

December 10, 2020

Study Completion Date

December 10, 2020

Conditions
Primary Soft-tissue Sarcoma
Interventions
DRUG

ABY-029

A minimum of 6 and a maximum of 12 adult patients with a diagnosis of primary soft-tissue sarcoma will be enrolled. Initial diagnostic biopsy specimens will be analyzed for EGFR positivity (an EGFR pathology score ≥ 1) by immunohistochemistry following routine diagnostic processing by Pathologist. Patients will be administered a single intravenous dose of ABY-029 1-3 hours before surgery.

Trial Locations (1)

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
collaborator

Dartmouth College

OTHER

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT03154411 - A Microdose Evaluation Study of ABY-029 in Primary Sarcoma | Biotech Hunter | Biotech Hunter